

Genetic burden associated with varying degrees of disease severity in endometriosis

Yadav Sapkota^{1,*}, John Attia^{2,3}, Scott D. Gordon¹, Anjali K. Henders¹, Elizabeth G. Holliday^{2,3}, Nilufer Rahmioglu⁴, Stuart MacGregor¹, Nicholas G. Martin¹, Mark McEvoy^{2,3}, Andrew P. Morris⁴, Rodney J. Scott^{3,5,6}, Krina T. Zondervan^{4,7}, Grant W. Montgomery¹, and Dale R. Nyholt^{1,8}

¹QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia ²Centre for Clinical Epidemiology and Biostatistics, School of Medicine and Public Health, University of Newcastle, Newcastle, New South Wales, Australia ³Public Health Research Program, Hunter Medical Research Institute, Newcastle, New South Wales, Australia ⁴Genetic and Genomic Epidemiology Unit, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK ⁵School of Biomedical Sciences and Pharmacy, University of Newcastle, Newcastle, New South Wales, Australia ⁶Division of Genetics, Hunter Area Pathology Service, Newcastle, New South Wales, Australia ⁷Nuffield Department of Obstetrics and Gynaecology, University of Oxford, John Radcliffe Hospital, Oxford, UK ⁸Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Queensland, Australia

*Correspondence address. Tel: +61-7-3362-0228; Fax: +61-7-3362-0111; E-mail: yadav.sapkota@qimrberghofer.edu.au

Submitted on February 17, 2015; resubmitted on March 31, 2015; accepted on April 10, 2015

ABSTRACT: Endometriosis is primarily characterized by the presence of tissue resembling endometrium outside the uterine cavity and is usually diagnosed by laparoscopy. The most commonly used classification of disease, the revised American Fertility Society (rAFS) system to grade endometriosis into different stages based on disease severity (I to IV), has been questioned as it does not correlate well with underlying symptoms, posing issues in diagnosis and choice of treatment. Using two independent European genome-wide association (GWA) datasets and top-level classification of the endometriosis cases based on rAFS [minimal or mild (Stage A) and moderate-to-severe (Stage B) disease], we previously showed that Stage B endometriosis has greater contribution of common genetic variation to its aetiology than Stage A disease. Herein, we extend our previous analysis to four endometriosis stages [minimal (Stage I), mild (Stage II), moderate (Stage III) and severe (Stage IV) disease] based on the rAFS classification system and compared the genetic burden across stages. Our results indicate that genetic burden increases from minimal to severe endometriosis. For the minimal disease, genetic factors may contribute to a lesser extent than other disease categories. Mild and moderate endometriosis appeared genetically similar, making it difficult to tease them apart. Consistent with our previous reports, moderate and severe endometriosis showed greater genetic burden than minimal or mild disease. Overall, our results provide new insights into the genetic architecture of endometriosis and further investigation in larger samples may help to understand better the aetiology of varying degrees of endometriosis, enabling improved diagnostic and treatment modalities.

Key words: endometriosis / rAFS classification system / genetic burden / polygenic prediction / genome-wide association studies

Introduction

Endometriosis is a complex gynaecological disease that affects 6–10% of women during reproductive age (Treloar *et al.*, 1999; Montgomery *et al.*, 2008) and 20–50% of women with infertility (Gao *et al.*, 2006). The disease is primarily characterized by the presence of tissue resembling endometrium outside the uterine cavity, most commonly the pouch of Douglas, ovaries and peritoneum. The most common symptoms include severe pelvic pain, heavy or irregular menstrual bleeding and pain during intercourse and exercise; however, some women remain

asymptomatic. Additional symptoms include infertility, lower abdominal and back pain, diarrhoea and/or constipation and chronic fatigue. Even though endometriosis is generally regarded as a benign disease, it can exhibit some characteristics of malignancy in terms of its progression and invasion of surrounding tissue (Giudice *et al.*, 1998; Thomas and Campbell, 2000; Campbell and Thomas, 2001) and in rare cases can undergo malignant transformation (Heaps *et al.*, 1990; Nyiraneza *et al.*, 2010). Risk factors of endometriosis include age, increased exposure to menstruation (shorter cycle length, longer duration of flow and nulliparity) and other factors related to estrogen levels, including

decreased body mass index and smoking history (Missmer *et al.*, 2004, 2010).

Diagnosis of endometriosis is based on clinical suspicion, pelvic examination, ultrasound and magnetic resonance imaging, but can only be confirmed by laparoscopy, an invasive surgical procedure (Duleba, 1997; Spaczynski and Duleba, 2003). Based on location, diameter and depth of lesions and density of adhesions, there are varying degrees of endometriosis. According to the revised American Fertility Society (rAFS) classification system (American Fertility Society, 1985; American Society for Reproductive Medicine, 1997), the disease is classified into one of four stages (I—minimal, II—mild, III—moderate and IV—severe). Women with minimal or mild endometriosis have superficial implants and very few adhesions whereas moderate or severe endometriosis is generally characterized by chocolate cysts and more severe adhesions. However, despite this rAFS standardization, there is a lack of correlation between clinical symptoms and surgical findings, posing a significant challenge in disease diagnosis and choice of therapeutic modalities (Ripps and Martin, 1992; Keltz and Olive, 1993; Olive and Schwartz, 1993; Stovall *et al.*, 1997). Patients presenting with minimal clinical symptoms may have advanced disease and conversely, women with infertility may have very few endometrial lesions. Consequently, the relevance—and biological basis for—the classification has been questioned. There is also debate about the role of surgical treatment for minimal disease (Johnson *et al.*, 2013; Practice Committee of the American Society for Reproductive Medicine, 2014). Hence, understanding the relationships between disease sub-types is highly relevant to developing policies for improved diagnostic methods and subsequent treatment options.

The exact cause of endometriosis is largely unknown, but is believed to be complex, involving multiple genetic and environmental risk factors. Studies have shown that genes influence susceptibility to endometriosis and the disease has an estimated total heritability of around 0.51 from twin studies (Treloar *et al.*, 1999) and a common single nucleotide polymorphism (SNP) based heritability of 0.26 (Lee *et al.*, 2013). Several independent genome-wide association (GWA) studies, including two by the International Endogene Consortium (IEC) (Painter *et al.*, 2011; Nyholt *et al.*, 2012), have corroborated the involvement of genetic factors in endometriosis. Earlier, we investigated the genetic burden of combined endometriosis stages [Stage A (rAFS Stage I or II) and Stage B (rAFS Stage III or IV)], using data from our GWA study for endometriosis (Painter *et al.*, 2011). The proportion of variance in case–control status explained by all variants tagged by the common variants assayed in the GWA data (i.e. common SNP-based heritability) was significantly higher for Stage B endometriosis (0.35) than that of Stage A disease (0.15) (Painter *et al.*, 2011). Similar results were observed when this ‘genetic loading’ was assessed by genetic risk scores derived from increasingly large SNP sets ranked on their statistical significance (Painter *et al.*, 2011), indicating substantially greater genetic loading for Stage B disease.

Here, we extend our previous analysis by examining the genetic loading from common genetic variation for more refined categories of endometriosis stage [rAFS Stage I (minimal), rAFS Stage II (mild), rAFS Stage III (moderate) and rAFS Stage IV (severe) disease] and compare the overlap in genetic burden among varying degrees of endometriosis. Considering the significant contribution of genetic factors to risk of endometriosis, this investigation may improve our current understanding of disease heterogeneity and the underlying genetic architecture of different endometriosis stages.

Materials and Methods

GWA datasets

We used two GWA datasets of European ancestry from our previous multi-ethnic GWA meta-analysis for endometriosis (Nyholt *et al.*, 2012). A detailed description of these datasets is presented elsewhere (Painter *et al.*, 2011; Nyholt *et al.*, 2012). Briefly, endometriosis cases ($n = 3181$) were recruited by the IEC [Australia (QIMR) = 2262; UK (OX) = 919] and all cases had a surgically confirmed diagnosis of endometriosis based on the medical records at the time of diagnosis. Disease stages were assessed retrospectively from surgical records by two independent gynaecologists with extensive experience in surgically diagnosing the disease (each for Australian and UK cases), following the rAFS classification system (American Fertility Society, 1985; American Society for Reproductive Medicine, 1997). Based on retrospectively assessed surgical records, Australian cases were assigned to different disease stages rASRM Stage I, II, III and IV. Because of uncertainty in ability to distinguish in particular between stages I and II based on retrospective assessment of records, the UK cases were grouped into Stage A (defined as peritoneal implants only) and Stage A+ (defined as some ovarian disease with some adhesions), and Stage B (rAFS III/IV). Both gynaecologists subsequently agreed there had been remarkable consistency in the way they had interpreted the clinical records, and that stage as recorded in the datasets could be combined by using the Stage B (rAFS III/IV) and Stage A (rAFS I/II or some ovarian disease with adhesions) classification. European ancestry-matched population controls ($n = 8075$) in the GWA data were from an Australian adolescent twin study (Wright and Martin, 2004), the Hunter Community Study (HCS) (McEvoy *et al.*, 2010) and the Wellcome Trust Case–control Consortium 2 (WTCCC2) [combined Australia-HCS (QIMR-HCS) = 2924; UK (OX) = 5151]. The QIMR-HCS and OX samples were genotyped on Illumina 670Quad (cases) and 610Quad (controls) using the services from deCODE genetics. HCS controls were genotyped at the University of Newcastle using Illumina 610Quad Beadchips. The WTCCC2 controls were genotyped at the Wellcome Trust Sanger Institute on Illumina HumanHapIM Beadchips.

Standard quality control measures were applied to individual QIMR-HCS and OX GWA datasets, as described earlier (Painter *et al.*, 2011; Nyholt *et al.*, 2012).

Genetic burden analysis

The aim of our genetic burden analysis was to evaluate the aggregate effects of many variants of small effect, using a prediction approach (International Schizophrenia Consortium *et al.*, 2009). We summarized variation across nominally associated loci into quantitative genetic risk scores and related the scores to disease status in independent samples. Although variants of small effect (for example, with genotype relative risk of 1.05) are unlikely to achieve even nominal significance, increasing proportions of true effects will be detected at increasingly liberal P -value thresholds, for example, $P < 0.1$ (~10% of all SNPs). Using such thresholds, we defined large sets of allele-specific scores in the discovery sample of the QIMR-HCS case–control set, by stratifying the total endometriosis cases ($n = 2262$) into one of four disease stages [rAFS Stage I ($n = 832$), rAFS Stage II ($n = 491$), rAFS Stage III ($n = 482$) and rAFS Stage IV ($n = 267$) disease] to generate risk scores for individuals in the target sample of the OX case–control set, by stratifying the total cases ($n = 919$) into one of three disease stages [Stage A ($n = 199$), Stage A+ ($n = 114$) and Stage B ($n = 380$) disease]. As a result, the QIMR-HCS and OX datasets consisted of four and three subsets, respectively. Endometriosis cases in both the QIMR-HCS and OX case–control sets with unknown disease stages were excluded from the analysis. Furthermore, for each of the subsets created from the QIMR-HCS and OX datasets, we used 2924 and 5151 common controls, respectively.

The term risk score is used instead of risk, as it is impossible to differentiate the minority of true risk alleles from the non-associated variants. In the discovery sample, we selected sets of allele-specific scores for SNPs with the following levels of significance: $P < 0.01, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9$ and 1.0 . For each individual in the target sample, we calculated the number of scored alleles that they possessed, each weighted by the log odds ratio (OR) from the discovery sample. To assess whether the aggregate scores reflect endometriosis risk, we tested for a higher mean score in cases compared with controls. Logistic regression was used to assess the relationship between target sample disease status and aggregate risk score, without any covariates. Nagelkerke's pseudo R^2 from the logistic regression analysis was used to assess the variance explained. Considering males in our control population, prediction was performed using only 488 833 autosomal SNPs overlapping in the QIMR-HCS and OX GWA datasets to avoid potential bias due to varying number of alleles in X chromosome between males and females. We also performed the predictions in reverse, using risk scores from the OX sample to predict affected status in the QIMR-HCS case-control set. Additional prediction analysis was conducted using potentially independent SNPs ($n \sim 128\ 000$) obtained from P -value based linkage-disequilibrium (LD) clumping in Plink ($-\text{clump-p1} \mid -\text{clump-p2} \mid -\text{clump-r2} \ 0.2 \ -\text{clump-kb} \ 500$) to see if the results are biased by SNPs in high LD.

Association analysis excluding minimal endometriosis

We further examined if true genetic effects are enriched after excluding endometriosis cases with minimal disease. As an illustrative example, we used the seven previously implicated SNPs in endometriosis (rs7521902, rs13394619, rs4141819, rs7739264, rs12700667, rs1537377 and rs10859871) (Nyholt et al., 2012). We performed allelic association tests for these SNPs in the QIMR-HCS case-control dataset, after excluding endometriosis cases with minimal disease (rAFS Stage I disease). Similar analysis after excluding Stage A disease was also conducted in the OX case-control dataset.

Results

The genetic risk scores derived from different endometriosis stages in the discovery sample of the QIMR-HCS case-control set significantly predicted case-control status in the corresponding disease stages in the target sample of the OX case-control set and vice-versa (Figs 1 and 2; and Table 1). The prediction results using all ($n = 488\ 833$) and potentially independent SNPs ($n \sim 128\ 000$) (data not shown) were not fundamentally different and hence results from all SNPs are presented. Stage A




Figure 1 Allele-specific score prediction for endometriosis, using Stages A, A+ and B in the OX case-control set as the target population and the QIMR-HCS case-control set as the discovery population. The proportion of variance explained in the target dataset on the basis of allele-specific scores derived from the discovery dataset is represented by Nagelkerke's pseudo R^2 , with its statistical significance (P). Among the 12 significance thresholds used in each prediction analysis, the most significant result (i.e. best P -value) is represented by arrow with corresponding R^2 (above) and its P -value (below). The colour of the arrows is graded based on the R^2 significance—the darker the arrow, the stronger the R^2 significance.




Figure 2 Allele-specific score prediction for endometriosis, using Stages I, II, III and IV in the QIMR-HCS case–control set as the target population and the OX case–control set as the discovery population. The proportion of variance explained in the target dataset on the basis of allele-specific scores derived from the discovery dataset is represented by Nagelkerke's pseudo R^2 , with its statistical significance (P). Among the 12 significance thresholds used in each prediction analysis, the most significant result (i.e. best P -value) is represented by arrow with corresponding R^2 (above) and its P -value (below). The colour of the arrows is graded based on the R^2 significance—the darker the arrow, the stronger the R^2 significance.

endometriosis cases in the OX case–control set were significantly predicted by rAFS Stage I disease in the QIMR-HCS case–control set, with the smallest P -value ($P = 3.15 \times 10^{-3}$) obtained for a genetic risk score including $\sim 10\%$ of the SNPs (Fig. 1 and Supplementary data, Fig. S1a). The result was significant, although the proportion of variance explained was small (maximum Nagelkerke's pseudo R^2 of 0.006; 0.60% of the variance). Genetic risk scores generated from other disease stages in the QIMR-HCS case–control set (rAFS Stage II–IV) did not predict the Stage A endometriosis cases in the OX case–control set (Fig. 1 and Supplementary data, Fig. S1b–d).

QIMR-HCS rAFS Stage I disease also significantly predicted Stage A+ endometriosis cases in the OX case–control set, with the lowest P -value ($P = 2.12 \times 10^{-3}$) obtained for a genetic risk score including $\sim 5\%$ of the SNPs (Fig. 1 and Supplementary data, Fig. S2a), which explained 0.95% of the proportion of variance. Similar prediction was also observed for the top $\sim 10\%$ of the SNPs. Stage A+ cases in the OX case–control set were also predicted by the QIMR-HCS rAFS Stage II

Table 1 Summary of polygenic prediction results showing OX and QIMR-HCS endometriosis stage(s) as 'Target' that are significantly ($P < 0.05$) predicted by QIMR-HCS and OX disease stages as 'Discovery'.

QIMR-HCS (Discovery)	OX (Target)	OX (Discovery)	QIMR-HCS (Target)
I	A, A+	A	I
II	A+, B	A+	II, III
III	A+, B	B	II, III, IV
IV	B		

and III disease (Fig. 1, Supplementary data, Fig. S2b and c); however, the results were weaker ($P = 0.035$ and 0.051 , respectively) and the variance explained was smaller than that of rAFS Stage I endometriosis

cases in the QIMR-HCS case–control set (0.44 and 0.38%, respectively). The rAFS Stage IV disease in the QIMR-HCS case–control set did not predict Stage A+ endometriosis cases in the OX case–control set (Fig. 1 and Supplementary data, Fig. S2d).

OX Stage B endometriosis cases were predicted by rAFS Stage II–IV disease in the QIMR-HCS case–control set (Fig. 1, Supplementary data, Fig. S3b–d); however, the strongest prediction was observed for rAFS Stage IV disease, with the lowest P -value ($P = 4.07 \times 10^{-5}$) obtained for genetic risk scores including ~20% of the SNPs (Fig. 1 and Supplementary data, Fig. S3d). The result was highly significant and the proportion of variance explained was 0.77%. For the QIMR-HCS rAFS Stage II and III, the best P -values ($P = 3.44 \times 10^{-3}$ and $P = 7.29 \times 10^{-4}$) were obtained for the score sets including ~1 and ~80% of the SNPs, which explained 0.39 and 0.52% of the variance, respectively (Fig. 1 and Supplementary data, Fig. S3b and c). QIMR-HCS rAFS Stage I did not predict the Stage B endometriosis cases in the OX case–control set (Fig. 1 and Supplementary data, Fig. S3e).

Results from genetic burden analysis for the OX case–control set as a discovery sample and the QIMR-HCS case–control set as a target sample were highly comparable with the results obtained from the QIMR-HCS dataset as a discovery and the OX dataset as a target sample. OX Stage A disease slightly predicted rAFS Stage I endometriosis cases in the QIMR-HCS case–control set (Fig. 2 and Supplementary data, Fig. S4a), with the smallest P -value ($P = 2.89 \times 10^{-2}$) obtained for genetic risk score including ~60% of the SNPs, although the proportion of variance explained was only 0.20%. Other disease stages in the QIMR-HCS case–control set were not predicted by scores from the OX Stage A disease (Fig. 2 and Supplementary data, Fig. S4b–d). OX Stage A+ disease predicted both rAFS Stage II and III cases in the QIMR-HCS case–control set (Fig. 2 and Supplementary data, Fig. S5b and c), with the prediction strongest for the rAFS Stage III cases, producing the smallest P -value ($P = 6.5 \times 10^{-4}$) for the risk score including ~5% of the SNPs, which explained 0.62% of the variance (Fig. 2 and Supplementary data, Fig. S5c). The OX Stage A+ disease did not predict rAFS Stage I and IV endometriosis cases in the QIMR-HCS case–control set (Fig. 2 and Supplementary data, Fig. S5a and d). Notably, OX Stage B disease predicted endometriosis cases of disease Stage II, III and IV in the QIMR-HCS case–control set, but it did not predict rAFS Stage I disease (Fig. 2 and Supplementary data, Fig. S6). Among the cases with rAFS Stages II, III and IV disease in the QIMR-HCS case–control set, the strongest prediction was observed for the rAFS Stage IV disease (Fig. 2 and Supplementary data, Fig. S6d), with the smallest P -value ($P = 2.0 \times 10^{-5}$) obtained for genetic risk score including ~30% of the SNPs, which explained 1.3% of the variance. For the rAFS Stages II and III disease, the proportions of the variance explained by ~30% of the associated SNPs ($P = 1.03 \times 10^{-2}$ and $P = 8.46 \times 10^{-5}$) were 0.34 and 0.81%, respectively (Fig. 1 and Supplementary data, Fig. S6b and c).

To explore whether specific classes of variants are responsible for part of the variance explained by common SNPs, we undertook analysis partitioning the variance tagged by SNPs into sets defined by functional annotation [SNPs within genes, SNPs in intergenic regions, non-synonymous SNPs and rare variants (minor allele frequency <5% in the combined QIMR-HCS and OX GWA datasets)]. For simplicity, we used the best prediction group—i.e. Stage IV in QIMR-HCS and Stage B in OX GWA datasets to investigate this question. We assigned

SNPs to RefSeq genes if they were positioned within 20 kb from the transcription start and stop sites of a gene. SNPs outside this region were considered to be intergenic. Accordingly, of the 488 833 autosomal SNPs, 295 424 were assigned to genes, 193 409 were intergenic, 4492 were non-synonymous and 23 362 were rare variants. The proportion of variance explained by genic SNPs was slightly higher [QIMR-HCS predicting OX: $R^2 = 0.67\%$; $P = 1.35 \times 10^{-4}$ and OX predicting QIMR-HCS: $R^2 = 1.3\%$; $P = 2.00 \times 10^{-5}$] as compared with intergenic SNPs (QIMR-HCS predicting OX: $R^2 = 0.25\%$; $P = 0.017$ and OX predicting QIMR-HCS: $R^2 = 0.41\%$; $P = 0.016$) (Supplementary data, Figs S7a and b and S8a and b). Additional analysis restricted to non-synonymous SNPs did not predict either group (QIMR-HCS predicting OX: $R^2 = 0.29\%$; $P = 0.012$ and OX predicting QIMR-HCS: $R^2 = 0.18\%$; $P = 0.012$; Supplementary data, Figs S7c and S8c), with similar results obtained for rare variants (QIMR-HCS predicting OX: $R^2 = 0.10\%$; $P = 0.13$ and OX predicting QIMR-HCS: $R^2 = 0.31\%$; $P = 0.037$; Supplementary data, Figs S7d and S8d). These data indicate that common SNPs within or close to genes, excluding non-synonymous variants, may contribute the bulk of the variance tagged by genome-wide autosomal SNPs; however these findings should be further investigated in larger sample size. Comparable predictions were obtained when we excluded SNPs within the eight robustly implicated endometriosis risk loci (defined by 2500 kb up- and downstream of the sentinel SNPs) that are polymorphic in Europeans (Nyholt et al., 2012; Sapkota et al., 2015), indicating that our results were not primarily driven by the few most strongly associated regions (Supplementary data, Fig. S9).

When we tested allelic associations of the top seven SNPs previously implicated in endometriosis after excluding QIMR-HCS cases with minimal disease (rAFS Stage I disease), except for rs13394619, we observed a slight increase in effect sizes compared with the effects estimated using all cases (Table II). These results were consistent in the independent OX case–control dataset, as well as in the combined (QIMR-HCS+OX) dataset.

Discussion

Endometriosis is an estrogen-dependent disorder affecting relatively younger women. Based on severity of the disease, endometriosis has been grouped into multiple stages, including minimal, mild, moderate, severe and more severe disease (American Fertility Society, 1985; American Society for Reproductive Medicine, 1997). We previously showed that moderate-to-severe (Stage B) endometriosis cases have higher common genetic variant contribution to aetiology compared with minimal or mild (Stage A) endometriosis (Painter et al., 2011). To investigate the relationship between disease stages in more detail, we re-assessed the genetic loading of endometriosis stages, using more refined disease stages of endometriosis cases in two European GWA datasets from the multi-ethnic GWA meta-analysis for endometriosis (Nyholt et al., 2012). For the purpose of gene discovery, the original top-level classification, including minimal or mild (Stage A) and moderate-to-severe (Stage B) endometriosis remains the most powerful and appropriate, and prediction between the QIMR-HCS and OX datasets for this classification remains significantly strongest. However, our more detailed results extend our earlier observations and show the genetic burden increases progressively for cases diagnosed from less to more severe disease, in agreement

Table II Effect sizes of the top seven endometriosis loci, with and without including endometriosis cases with minimal disease.

Chr	SNP	Position (bp)	RA	OA	QIMR-HCS				OX				QIMR-HCS+OX			
					All cases		Excluding Stage I cases		All cases		Excluding Stage A cases		All cases		Excluding minimal disease	
					OR (95% CI)	P	OR (95% CI)	P	OR (95% CI)	P	OR (95% CI)	P	OR (95% CI)	P	OR (95% CI)	P
1	rs7521902	22490724	A	C	1.16 (1.06–1.27)	8.89E–04	1.21 (1.10–1.34)	2.06E–04	1.12 (1.00–1.26)	4.97E–02	1.12 (0.99–1.27)	7.63E–02	1.15 (1.07–1.23)	1.43E–04	1.17 (1.09–1.27)	6.83E–05
2	rs13394619	11727507	G	A	1.10 (1.02–1.19)	1.73E–02	1.09 (0.99–1.19)	8.12E–02	1.12 (1.02–1.25)	1.63E–02	1.14 (1.02–1.27)	2.28E–02	1.11 (1.04–1.18)	7.70E–04	1.10 (1.03–1.19)	5.19E–03
2	rs4141819	67864675	C	T	1.17 (1.08–1.27)	2.38E–04	1.29 (1.17–1.41)	2.30E–07	1.16 (1.05–1.29)	4.52E–03	1.17 (1.04–1.31)	8.46E–03	1.17 (1.10–1.25)	3.12E–06	1.24 (1.15–1.34)	1.29E–08
6	rs7739264	19785588	T	C	1.15 (1.05–1.23)	7.48E–04	1.18 (1.08–1.28)	3.81E–04	1.18 (1.06–1.30)	1.33E–03	1.19 (1.06–1.33)	2.74E–03	1.16 (1.09–1.23)	3.30E–06	1.18 (1.10–1.27)	3.04E–06
7	rs12700667	25901639	A	G	1.23 (1.12–1.35)	5.35E–06	1.28 (1.15–1.43)	3.19E–06	1.19 (1.06–1.35)	3.49E–03	1.28 (1.12–1.47)	3.18E–04	1.22 (1.14–1.32)	7.03E–08	1.28 (1.18–1.39)	4.18E–09
9	rs1537377	22169700	C	T	1.13 (1.04–1.22)	3.01E–03	1.17 (1.07–1.29)	5.52E–04	1.16 (1.05–1.28)	4.76E–03	1.20 (1.07–1.34)	1.30E–03	1.14 (1.07–1.21)	4.71E–05	1.18 (1.10–1.27)	2.67E–06
12	rs10859871	95711876	C	A	1.16 (1.07–1.26)	4.17E–04	1.18 (1.07–1.30)	7.64E–04	1.19 (1.07–1.32)	1.59E–03	1.19 (1.06–1.33)	4.36E–03	1.17 (1.10–1.25)	2.54E–06	1.18 (1.10–1.27)	1.07E–05

Chr, chromosome; position, chromosomal position (bp) based on Human Build 37 (GRCh37/hg19); RA, risk allele; OA, other allele; OR, odds ratio; CI, confidence interval.

with previous results showing stronger evidence for genetic contribution to severe disease. Stronger results were observed from severe disease (rAFS Stage IV) in QIMR-HCS as discovery sample predicting Stage B disease in OX and the reverse. Despite small sample sizes, results from different disease stages from QIMR-HCS as discovery sample provided the best prediction for equivalent stages in the OX sample.

While there is a general trend for stronger genetic contributions to severe disease, the prediction of Stage A and A+ diseases in the OX from rAFS Stage I in QIMR-HCS suggest that weaker genetic effects in the early stage of endometriosis are not just the consequence of difficulties in diagnosis. There may be differences in genetic architecture between minimal and the more severe stages of disease. The observed weaker genetic effects in minimal disease were further supported by a slight enrichment in effect sizes of previously implicated endometriosis loci, after excluding cases with minimal disease (Table I).

There is genetic overlap between minimal–mild (Stage A) and moderate-to-severe (Stage B) disease. However in the current study, the early stages of endometriosis exhibit evidence for different genetic risk compared with the other disease stages. Risk scores derived from the early stage of endometriosis could predict themselves only (Fig. 1 and Supplementary data, Figs S1 and S4). Minimal endometriosis in the QIMR-HCS case–control set predicted mild disease in the OX case–control set (Fig. 1 and Supplementary data, Fig. S2a), indicating some shared aetiology between these early stages of endometriosis that may be different from more severe disease stages. When the analysis was reversed, OX minimal disease provided weaker prediction of minimal endometriosis cases in the QIMR-HCS dataset (Fig. 2 and Supplementary data, Fig. S4a) but not other stages of disease. There is reduced statistical power using the OX dataset for prediction because of the number of minimal endometriosis cases in the OX case–control set ($n = 199$) compared with the QIMR-HCS case–control set ($n = 832$). Further investigation with a larger sample size is required to confirm these emerging hypotheses.

Higher shared genetic burden was observed between mild and moderate endometriosis cases. Both mild and moderate endometriosis cases in the QIMR-HCS case–control set predicted multiple disease stages, including mild disease in the OX case–control set (Fig. 1 and Supplementary data, Fig. S2b and c) and vice-versa (Fig. 2 and Supplementary data, Fig. S5b and c). Furthermore, the QIMR-HCS mild disease also predicted moderate-to-severe endometriosis cases in the OX case–control set (Fig. 1 and Supplementary data, Fig. S3b) and similar results were obtained from the reverse analysis (Fig. 1 and Supplementary data, Fig. S6b). While moderate-to-severe (Stage B) disease in the OX sample was predicted by risk scores for mild, moderate and severe diseases, shifts in prediction moved from moderate to severe cases. The OX Stage A+ disease was predicted by risk scores for QIMR-HCS mild (rAFS Stage II) and moderate (rAFS Stage III) disease (Fig. 1 and Supplementary data, Fig. S2a–c). Consistent with our previous results (Painter et al., 2011), moderate-to-severe endometriosis exhibited greater genetic burden, for which the proportion of variance explained by genetic risk scores was higher (up to 1.3%) compared with minimal or mild disease. Both moderate and severe endometriosis cases in the QIMR-HCS case–control set predicted moderate-to-severe disease in the OX case–control set (Fig. 1, Supplementary data, Fig. S3c and d) and the reverse analysis corroborated these results (Fig. 2 and Supplementary data, Fig. S6c and S6d).

These results should be interpreted in consideration of several limitations. First, disease stages of endometriosis cases were scored retrospectively, which may be less accurate than a prospective grading system. Second, the rAFS scores used to classify disease stage do not correlate well with all clinical features and that this classification system, even though the most commonly used, has obvious drawbacks and that another classification system often used—peritoneal versus ovarian (and rectovaginal) is confounded with the rAFS system. As suggested by the fact that Stage A+ in OX is more strongly predictive of rAFS Stage III, not Stage II in QIMR-HCS, we may be looking at genetic differences between peritoneal versus ovarian disease. In addition to the traditional rAFS classification system, other grading systems including the ENZIAN classification (Tuttles et al., 2005) and the endometriosis fertility index (Adamson and Pasta, 2010) have been suggested, which may improve endometriosis staging. Genetic marker data can provide insights into similarities and differences in disease architecture, hence, there is a need for systematic studies on large samples with detailed clinical and/or disease presentation including prospective data on rAFS stage. Finally, although current sample sizes lack power to identify enough genetic risk factors to enable accurate prediction, they have good power to identify associations that provide valuable insight into the underlying genetics of complex diseases, including endometriosis (Dudbridge, 2013). The risk prediction will become more feasible as sample sizes for the association analyses grow several orders of magnitude greater than current endometriosis studies.

In conclusion, extending our analysis of genetic risk scores derived from two large European GWA datasets from our previous multi-ethnic GWA meta-analysis of endometriosis, we show genetic factors contribute to minimal disease and may differ from more severe endometriosis. As shown by the higher proportion of variance explained, more severe endometriosis cases exhibited greater genetic loading than minimal or mild disease. The genetic burden generally increased from less severe (minimal) to more severe disease, consistent with disease progression. There was significant prediction for minimal disease between independent datasets, suggesting the minimal disease may be ‘disease’ rather than a physiological phenomenon; however, the genetic contribution to this group was weaker and hence excluding these minimal endometriosis cases may improve association signals in GWA studies for endometriosis. Consequently, well-defined diagnostic and treatment modalities considering both the genetic differences and overlaps among the different stages of endometriosis may be required for a better management of the disease.

Supplementary data

Supplementary data are available at <http://molehr.oxfordjournals.org/> online.

Acknowledgements

We would like to thank all the study participants in the QIMR, OX, HCS and WTCCC2 endometriosis studies that formed the basis of the current study. We also thank many hospital directors and staff, gynaecologists, general practitioners and pathology services in Australia and UK who provided assistance with confirmation of diagnoses.

Authors' roles

Y.S.: design (QIMR part), analysis and interpretation, drafting manuscript and final approval; J.A.: design (HCS part), revision for critical content and final approval; S.D.G.: design (QIMR part), revision for critical content and final approval; A.K.H.: design (QIMR part), revision for critical content and final approval; E.G.H.: design (HCS part), revision for critical content and final approval; N.R.: design (OX part), revision for critical content and final approval; S.M.: design (QIMR part), revision for critical content and final approval; N.G.M.: design and sample collection (QIMR part), revision for critical content and final approval; M.M.: design (HCS part), revision for critical content and final approval; A.P.M.: design (OX part), revision for critical content and final approval; R.J.S.: design (HCS part), revision for critical content and final approval; K.T.Z.: conception and design (OX part), revision for critical content and final approval; G.W.M.: conception and design (QIMR part), interpretation, revision for critical content and final approval; D.R.N.: conception and design (QIMR part), interpretation, revision for critical content and final approval.

Funding

The QIMR study was supported by grants from the National Health and Medical Research Council (NHMRC) of Australia (241944, 339462, 389927, 389875, 389891, 389892, 389938, 443036, 442915, 442981, 496610, 496739, 552485 and 552498), the Cooperative Research Centre for Discovery of Genes for Common Human Diseases (CRC), Cerylid Biosciences (Melbourne) and donations from N. Hawkins and S. Hawkins. The work presented here was supported by a grant from the Wellcome Trust (WT084766/Z/08/Z) and makes use of WTCCC2 control data generated by the Wellcome Trust Case-control Consortium. A full list of the investigators who contributed to the generation of these data is available from <http://www.wtccc.org.uk>. Funding for the WTCCC project was provided by the Wellcome Trust under awards 076113 and 085475. D.R.N. was supported by the NHMRC Fellowship (339462 and 613674) and the ARC Future Fellowship (FT0991022) schemes. E.G.H. (631096) and G.W.M. (339446, 619667) were supported by the NHMRC Fellowships Scheme. The HCS was funded by the University of Newcastle, the Gladys M Brawn Fellowship scheme and the Vincent Fairfax Family Foundation in Australia. A.P.M. was supported by a Wellcome Trust Senior Research Fellowship. K.T.Z. is supported by a Wellcome Trust Research Career Development Fellowship (WT085235/Z/08/Z).

Conflict of interest

None declared.

References

Adamson GD, Pasta DJ. Endometriosis fertility index: the new, validated endometriosis staging system. *Fertil. Steril.* 2010;**94**:1609–1615.

American Fertility Society. Revised American Fertility Society classification of endometriosis: 1985. *Fertil. Steril.* 1985;**43**:351–352.

American Society for Reproductive Medicine. Revised American Society for Reproductive Medicine classification of endometriosis: 1996. *Fertil. Steril.* 1997;**67**:817–821.

Campbell IG, Thomas EJ. Endometriosis: candidate genes. *Hum. Reprod. Update* 2001;**7**:15–20.

Dudbridge F. Power and predictive accuracy of polygenic risk scores. *PLoS Genet.* 2013;**9**:e1003348.

Duleba AJ. Diagnosis of endometriosis. *Obstet. Gynecol. Clin. North Am.* 1997;**24**:331–346.

Gao X, Outley J, Botteman M, Spalding J, Simon JA, Pashos CL. Economic burden of endometriosis. *Fertil. Steril.* 2006;**86**:1561–1572.

Giudice LC, Tazuke SI, Swiersz L. Status of current research on endometriosis. *J. Reprod. Med.* 1998;**43**:252–262.

Heaps JM, Nieberg RK, Berek JS. Malignant neoplasms arising in endometriosis. *Obstet. Gynecol.* 1990;**75**:1023–1028.

International Schizophrenia Consortium, Purcell SM, Wray NR, Stone JL, Visscher PM, O'Donovan MC, Sullivan PF, Sklar P. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. *Nature* 2009;**460**:748–752.

Johnson NP, Hummelshoj L, World Endometriosis Society Montpellier Consortium. Consensus on current management of endometriosis. *Hum. Reprod.* 2013;**28**:1552–1568.

Keltz MD, Olive DL. Diagnostic and therapeutic options in endometriosis. *Hosp. Pract.* 1993;**28**:15–6, 20–2, 31.

Lee SH, Harold D, Nyholt DR, ANZGene Consortium, International Endogene Consortium, Genetic, Environmental Risk for Alzheimer's disease Consortium, Goddard ME, Zondervan KT, Williams J, Montgomery GW *et al.* Estimation and partitioning of polygenic variation captured by common SNPs for Alzheimer's disease, multiple sclerosis and endometriosis. *Hum. Mol. Genet.* 2013;**22**:832–841.

McEvoy M, Smith W, D'Este C, Duke J, Peel R, Schofield P, Scott R, Byles J, Henry D, Ewald B *et al.* Cohort profile: the Hunter Community Study. *Int. J. Epidemiol.* 2010;**39**:1452–1463.

Missmer SA, Hankinson SE, Spiegelman D, Barbieri RL, Marshall LM, Hunter DJ. Incidence of laparoscopically confirmed endometriosis by demographic, anthropometric, and lifestyle factors. *Am. J. Epidemiol.* 2004;**160**:784–796.

Missmer SA, Chavarro JE, Malspeis S, Bertone-Johnson ER, Hornstein MD, Spiegelman D, Barbieri RL, Willett WC, Hankinson SE. A prospective study of dietary fat consumption and endometriosis risk. *Hum. Reprod.* 2010;**25**:1528–1535.

Montgomery GW, Nyholt DR, Zhao ZZ, Treloar SA, Painter JN, Missmer SA, Kennedy SH, Zondervan KT. The search for genes contributing to endometriosis risk. *Hum. Reprod. Update* 2008;**14**:447–457.

Nyholt DR, Low SK, Anderson CA, Painter JN, Uno S, Morris AP, Macgregor S, Gordon SD, Henders AK, Martin NG *et al.* Genome-wide association meta-analysis identifies new endometriosis risk loci. *Nat. Genet.* 2012;**44**:1355–1359.

Nyiraneza C, Marbaix E, Smets M, Galant C, Sempoux C, Dahan K. High risk for neoplastic transformation of endometriosis in a carrier of Lynch syndrome. *Fam. Cancer* 2010;**9**:383–387.

Olive DL, Schwartz LB. Endometriosis. *N. Eng. J. Med.* 1993;**328**:1759–1769.

Painter JN, Anderson CA, Nyholt DR, Macgregor S, Lin J, Lee SH, Lambert A, Zhao ZZ, Roseman F, Guo Q *et al.* Genome-wide association study identifies a locus at 7p15.2 associated with endometriosis. *Nat. Genet.* 2011;**43**:51–54.

Practice Committee of the American Society for Reproductive Medicine. Treatment of pelvic pain associated with endometriosis: a committee opinion. *Fertil. Steril.* 2014;**101**:927–935.

Ripps BA, Martin DC. Correlation of focal pelvic tenderness with implant dimension and stage of endometriosis. *J. Reprod. Med.* 1992;**37**:620–624.

Sapkota Y, Low SK, Attia J, Gordon SD, Henders AK, Holliday EG, MacGregor S, Martin NG, McEvoy M, Morris AP *et al.* Association

- between endometriosis and the interleukin 1A (IL1A) locus. *Hum. Reprod.* 2015;**30**:239–248.
- Spaczynski RZ, Duleba AJ. Diagnosis of endometriosis. *Semin. Reprod. Med.* 2003;**21**:193–208.
- Stovall DW, Bowser LM, Archer DF, Guzick DS. Endometriosis-associated pelvic pain: evidence for an association between the stage of disease and a history of chronic pelvic pain. *Fertil. Steril.* 1997;**68**:13–18.
- Thomas EJ, Campbell IG. Molecular genetic defects in endometriosis. *Gynecol. Obstet. Invest.* 2000;**50**(Suppl 1):44–50.
- Treloar SA, O'Connor DT, O'Connor VM, Martin NG. Genetic influences on endometriosis in an Australian twin sample. *Fertil. Steril.* 1999;**71**:701–710.
- Tuttles F, Keckstein J, Ulrich U, Possover M, Schweppe KW, Wustlich M, Buchweitz O, Greb R, Kandolf O, Mangold R et al. [ENZIAN-score, a classification of deep infiltrating endometriosis]. *Zentralbl. Gynakol.* 2005;**127**:275–281.
- Wright MJ, Martin NG. Brisbane Adolescent Twin Study: outline of study methods and research projects. *Aust. J. Psychol.* 2004;**56**:65–78.